Unione Europea - finlandese - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - rintojen kasvaimet - antineoplastiset aineet - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Unione Europea - finlandese - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil hydrochloride - paksusuolen vajaatoiminta - antineoplastiset aineet - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Unione Europea - finlandese - EMA (European Medicines Agency)

nordic group b.v. - tegafur, gimeracil, oteracil - mahalaukun kasvaimet - antineoplastiset aineet - teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5. - as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting.

Unione Europea - finlandese - EMA (European Medicines Agency)

sandoz gmbh - trastutsumabi - breast neoplasms; stomach neoplasms - antineoplastiset aineet - treatment of metastatic and early breast cancer and metastatic gastric cancer (mgc).

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - ibuprofenum - tabletti, kalvopäällysteinen - 200 mg - ibuprofeeni

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - ibuprofen - tabletti, kalvopäällysteinen - 400 mg - ibuprofeeni

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

ratiopharm gmbh - sodium alendronate trihydrate - tabletti, kalvopäällysteinen - 70 mg - alendronaatti

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

menarini international operations luxembourg s.a. - dexketoprofenum trometamolum - rakeet oraaliliuosta varten - 25 mg - deksketoprofeeni

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

le vet. beheer b.v. - metoclopramide hydrochloride - injektioneste, liuos - 2.5 mg/ml - metoklopramidi

Finlandia - finlandese - Fimea (Suomen lääkevirasto)

le vet. beheer b.v. - metoclopramide hydrochloride - injektioneste, liuos - 5 mg/ml - metoklopramidi